Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02902939
Other study ID # 20161101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date July 19, 2018

Study information

Verified date July 2018
Source Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pro- and anti-inflammatory response during the formation of the critical state develops at the same time. Because of its balanced or unbalanced systemic inflammation can be either aborted or able to lead to multiple organ failure. With regard to sepsis, systemic inflammatory response characteristics are well understood, is not achieved in respect of the "sterile" inflammation.

Extracorporeal circulation is a clinical model of systemic inflammatory response due to non-physiological activation of tissue factor in the extracorporeal perfusion, the use of non-pulsatile circulation mode, intentional / unintentional hypothermia, bacterial translocation from the gastrointestinal tract and perfusion deficit.

We have proved that the monocytes demonstrate suppressor function, which can be a predictor of complications from cardiac surgery patients.

The most important component of the formation of multiple organ failure (MOF) in critically ill patients is immunosuppression.

During the study of experimental and clinical tumor growth process scientists has provided a new population of immature myeloid cells (myeloid suppressor cells or suppressor cells of myeloid origin, MDSC). Most of the works have been devoted to the role of MDSC in the development of tumors, where it has been clearly shown that this cell population has an undoubted effect of immune suppression. However, recent studies show that the role of MDSC is not limited to cancer process, but extends to chronic or acute inflammation.

The aim of this study is to determine the role of MDSC in the development of immune suppression and complications after heart surgery carried out under cardiopulmonary bypass.


Description:

The use of MEC systems can be useful to prevent the MDSC activation after cardiac surgery.

The procedures to modulate the cytokines concentration can be useful to prevent the MDSC activation after cardiac surgery.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 19, 2018
Est. primary completion date July 19, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. the patients with ischemia heart disease and/or valvular heart disease,

2. signed inform consent,

3. CABG and/or valve replacement/plastic procedures.

Exclusion Criteria:

1) congenital heart disease.

Study Design


Related Conditions & MeSH terms

  • Heart Failure
  • Insufficiency; Cardiac, Complicating Surgery
  • Systemic Inflammatory Response Syndrome

Intervention

Device:
minimal extracorporeal circulation (MEC)
We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
Procedure:
The cytokines modulations
We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)

Locations

Country Name City State
Russian Federation Georgy Plotnikov Kemerovo

Sponsors (1)

Lead Sponsor Collaborator
Research Institute for Complex Problems of Cardiovascular Diseases, Russia

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary MOF-free days 28 day
Secondary ICU length of stay 28 day
Secondary the incidents of infection complications 28 day
See also
  Status Clinical Trial Phase
Completed NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass N/A
Completed NCT02563652 - Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?
Recruiting NCT01157299 - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO N/A
Completed NCT01388725 - Comparison the Value of Several Biomarkers of Sepsis N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Not yet recruiting NCT03617796 - Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
Completed NCT03876041 - Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome Phase 4
Recruiting NCT05608096 - European Registry for Hemadsorption in Sepsis With the Seraph Filter
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT02568410 - Platelets as Regulators of Inflammation in Cardiac Surgery
Completed NCT01636232 - Vitamin D and Critically Ill Patients N/A
Completed NCT01020409 - INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery Phase 4
Completed NCT04624776 - Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest Phase 2
Recruiting NCT05172739 - Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC Phase 4
Recruiting NCT02957175 - Immunophenotyping of Patients With Postoperative SIRS
Completed NCT02320539 - MicroRNA Diagnostics in Subarachnoid Hemorrhage 2 N/A
Completed NCT01708759 - IL8 Monitoring and Its Correlation With 251-gene Polymorphism N/A
Terminated NCT00708799 - Efficacy of Macrolide Immunomodulation in Severe Sepsis. Phase 2
Recruiting NCT04580680 - Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)
Recruiting NCT05663216 - Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome